Last updated: February 16, 2026
Overview
NDC 68180-0181 refers to a monoclonal antibody product used in oncology, originating from the drug Pembrolizumab. This drug, marketed as Keytruda, is approved for multiple cancers, including melanoma and non-small cell lung cancer (NSCLC). The drug's financial landscape stems from a mature market with high demand, influenced by global approvals and ongoing clinical trials expanding indications. The current market size for Pembrolizumab approximates $15 billion annually, with growth driven by label expansions and increasing use in combination therapies.
Market Penetration and Competitive Landscape
- Market Penetration: Keytruda holds approximately 70% of the global PD-1 inhibitor market (as of 2022), competing mainly with nivolumab (Opdivo) and atezolizumab (Tecentriq).
- Indications: Approved for over 20 indications in over 100 countries, including melanoma, NSCLC, head and neck cancers, and bladder cancer.
- Market Share Trends: In the U.S., Keytruda's share declined from 74% to 69% in 2022 as competitors expanded their portfolios, but remains dominant.
- Competitive Dynamics:
- Nivolumab maintains a close market share (~25–30%), especially in non-small cell lung and renal cancers.
- Atezolizumab, durvalumab, and others account for remaining share.
- Price competition is limited by label-driven formulary preferences and established brand loyalty.
Pricing Analysis
- Current Pricing (U.S.):
- List price for a 200 mg vial: approximately $10,000.
- Typical dose: 200 mg every 3 weeks (or as per indication), leading to annual costs exceeding $170,000 per patient.
- Pricing Trends:
- The list price remains relatively stable, with minor adjustments.
- Negotiated outpatient and institutional discounts lower actual payer costs by 10–20%.
- Price for Biosimilars:
- No biosimilar versions approved or marketed yet.
- Biosimilars expected in 3–5 years, potentially reducing prices by 20–30%.
Pipeline and Indication Expansion
- Ongoing Trials: Pembrolizumab is in trials for colorectal, gastric, and pediatric cancers.
- Potential Market Impact: Successful expansion could increase annual revenue by 10–15%, assuming regulatory approval.
Pricing Projections (Next 3–5 Years)
| Year |
List Price (USD) |
Average Price after Discounts |
Estimated Revenue (USD billions) |
Notes |
| 2023 |
10,000 |
8,000 |
14–15 |
Stable price, current market penetration |
| 2024 |
10,000 |
8,000 |
15–16 |
Market growth continues, new indications |
| 2025 |
9,800 |
7,840 |
16–17 |
Biosimilar competition begins in early phase |
| 2026 |
9,800 |
7,840 |
16–17 |
Biosimilars gain market share, price erosion begins |
The revenue outlook assumes stable or increasing use in approved indications, with slight downward pressure from biosimilar entry.
Regulatory and Policy Factors
- Pricing Regulations: U.S. inflation-adjusted pricing pressures, stepped discounts, and policy initiatives aim to curb drug costs.
- Global Market: Prices vary across markets; Europe and Asia often have negotiated prices notably lower than U.S. levels.
Risks
- Biosimilar market entry could lower pricing.
- Expanded indications could drive revenue but also increase competition and scrutiny.
- Regulatory shifts or policy reforms could impact pricing structures.
Key Takeaways
- NDC 68180-0181 (Keytruda) is a leading PD-1 immunotherapy with a dominant market position.
- Current prices remain stable, but biosimilar competition looms, likely reducing prices by 20–30% in 3–5 years.
- Revenue projections suggest continued growth, heavily reliant on indication expansion.
- Market share is unlikely to significantly shift unless new competitors or products emerge.
- Regulatory policies and biosimilar rollouts are key risks to future pricing and revenue.
Frequently Asked Questions
1. What will be the impact of biosimilars on NDC 68180-0181’s pricing?
Biosimilars are expected to enter markets within 3–5 years. They could reduce prices by 20–30%, impacting revenue, especially as market penetration increases.
2. How does Keytruda’s pricing compare with competitors?
Its list price is similar to nivolumab, with slight differences due to dosing and negotiating discounts. Both drugs are premium priced with minimal variation among top competitors.
3. Will new indications significantly expand revenue?
Yes. Successful approval in additional indications, especially larger markets like colorectal or gastric cancers, could incrementally increase annual revenue by 10–15%.
4. What factors might influence future price adjustments?
Regulatory policies, market competition, biosimilar approvals, and negotiations with payers can drive gradual price reductions or discounts.
5. How does geographic variation affect pricing?
Prices in Europe and Asia are generally lower due to negotiated healthcare agreements, affecting overall revenue from international markets.
Sources
[1] IQVIA, "PharmaIQ," 2022.
[2] Evaluate Pharma, "Global Oncology Market Report," 2022.
[3] US Food and Drug Administration (FDA), drug approval databases.
[4] Medicare and private payer formulary reports, 2022.
